Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WEZLANA vs METHYLPHENIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Treatment of active psoriatic arthritis in adults
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
IV: 500 mg every 12 hours over 60 minutes.
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
WEZLANA is a monoclonal antibody expected to be degraded into small peptides and amino acids via catabolic pathways; no specific metabolic enzymes involved.
Methylphenidate is primarily metabolized via deesterification to ritalinic acid (inactive) by carboxylesterase enzymes (CES1A1 in the liver). Minor metabolism occurs via hydroxylation, oxidation, and conjugation.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
95% bound to albumin.
~30% (primarily to albumin)
0.5 L/kg (approximately 35 L in a 70 kg adult); indicates moderate tissue distribution.
13–28 L/kg (high due to extensive tissue distribution)
Oral: 85% (due to first-pass metabolism); Intravenous: 100%.
Oral immediate-release: 10–20% (extensive first-pass metabolism); Extended-release: comparable to IR. Transdermal: ~50–60% of total dose.
GFR ≥60 m L/min: no adjustment; GFR 30-59: 250 mg every 12 hours; GFR 15-29: 250 mg every 24 hours; GFR <15: 250 mg every 48 hours.
GFR 30-89 m L/min: No adjustment recommended. GFR <30 m L/min: Use with caution; reduce dose by 50% due to potential accumulation. Hemodialysis: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
2-12 years: 10 mg/kg IV every 12 hours (max 500 mg/dose); ≥12 years: same as adult.
Weight-based: 0.3-0.6 mg/kg/dose up to 0.8 mg/kg/day. Immediate-release: 2.5-5 mg twice daily initially; titrate by 2.5-5 mg weekly; maximum 60 mg/day. Extended-release (age ≥6): 18 mg once daily; titrate by 18 mg weekly; maximum 54 mg/day.
No specific dose adjustment except based on renal function; monitor for prolonged QT interval.
Start at 2.5 mg twice daily; titrate slowly by 2.5-5 mg every 2-3 weeks; maximum 40 mg/day. Monitor for cardiovascular effects, anxiety, and insomnia.
No FDA black box warning.
Methylphenidate has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Carefully consider the risks of abuse before prescribing, and monitor for signs of abuse and dependence during therapy.
Increased risk of infections, including serious infections,Hypersensitivity reactions,Potential for immunogenicity and loss of efficacy,Pre-treatment evaluation for tuberculosis infection recommended,Avoid use of live vaccines during treatment
Serious cardiovascular events including sudden death in patients with pre-existing cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events such as psychosis or mania,Suppression of growth in children,Seizures,Priapism,Peripheral vasculopathy including Raynaud's phenomenon,Drug dependence and withdrawal upon abrupt discontinuation
History of hypersensitivity to WEZLANA or any of its excipients,Clinically significant active infection
Hypersensitivity to methylphenidate or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Motor tics or a family history or diagnosis of Tourette's syndrome,Severe anxiety, tension, agitation,Pre-existing structural cardiac abnormalities or serious heart arrhythmias
No significant food interactions identified. Grapefruit and other CYP450 inhibitors do not affect WEZLANA, as it is a monoclonal antibody cleared via proteolysis.
Avoid high-fat meals near dosing of extended-release formulations as they may delay absorption or alter drug release. Generally, methylphenidate can be taken with or without food, but consistency is advised. Acidic foods (e.g., citrus fruits, cola) may decrease absorption; separate by at least 1 hour.
First trimester: Potential for major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Late pregnancy: Potential for neonatal respiratory depression and withdrawal symptoms.
First trimester: Limited data; possible increased risk of congenital heart defects. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties).
Not recommended during breastfeeding due to high lipid solubility and potential for infant toxicity. M/P ratio unknown; expected to concentrate in breast milk.
M/P ratio: 2.4. Excreted in breast milk; potential for infant agitation and insomnia. Avoid breastfeeding or use with caution, monitoring infant for adverse effects.
Due to increased volume of distribution and enhanced renal clearance in pregnancy, consider increasing dose by 20-30% in second and third trimesters. Monitor therapeutic drug levels to guide adjustments.
Pharmacokinetic changes: Increased clearance (up to 50%) and volume of distribution in late pregnancy, potentially requiring dose increases to maintain efficacy. Individualize based on clinical response and tolerability; postpartum dose may need reduction.
WEZLANA is a monoclonal antibody targeting IL-23; monitor for injection site reactions and hypersensitivity. Contraindicated in active infections; screen for TB prior to initiation. Do not administer live vaccines during treatment.
Methylphenidate is a first-line stimulant for ADHD and narcolepsy. Immediate-release formulations have a short duration (3-4 hours); extended-release formulations provide coverage for 8-12 hours. Monitor for appetite suppression, insomnia, and growth in children. Use with caution in patients with hypertension, seizures, or tic disorders. Avoid concomitant use with MAOIs.
Report any signs of infection, such as fever, cough, or skin redness.,Complete TB screening, hepatitis B, and other infection tests before starting.,Avoid live vaccines (e.g., MMR, varicella) during and for 6 months after treatment.,Store WEZLANA in the refrigerator, do not freeze; protect from light.,Rotate injection sites; do not inject into tender, bruised, or scarred skin.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow extended-release capsules/tablets whole; do not crush or chew.,Take last dose of immediate-release at least 6 hours before bedtime to avoid insomnia.,Avoid alcohol while taking methylphenidate.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Inform your doctor if you have a history of heart problems, high blood pressure, or seizures.,Report any new or worsening psychiatric symptoms (e.g., agitation, hallucinations).,Store at room temperature away from moisture and heat.
No interactions on record
"Bepridil, a calcium channel blocker with antianginal and class I/IV antiarrhythmic properties, may reduce the antihypertensive efficacy of methylphenidate by attenuating its central sympathomimetic effects. Methylphenidate, a CNS stimulant, typically increases blood pressure via enhanced norepinephrine and dopamine activity, but bepridil's calcium channel blockade in vascular smooth muscle and potential negative chronotropic effects can counteract these pressor responses, leading to diminished blood pressure control. This interaction is particularly relevant in patients using methylphenidate for ADHD or narcolepsy who have comorbid hypertension managed with bepridil, potentially resulting in elevated blood pressure readings and reduced therapeutic benefit."
"Methylphenidate is a moderate inhibitor of CYP2D6, the primary enzyme responsible for the metabolism of delavirdine. Co-administration can lead to elevated delavirdine plasma concentrations, increasing the risk of QT prolongation, hepatotoxicity, and other dose-related toxicities. Clinically, this may manifest as arrhythmias, elevated liver enzymes, or severe rash."
"Lofexidine, a centrally acting alpha-2 adrenergic agonist, reduces sympathetic outflow leading to decreased blood pressure. Methylphenidate, a central nervous system stimulant, can elevate blood pressure via sympathomimetic effects. When co-administered, lofexidine may partially antagonize the pressor effects of methylphenidate, potentially reducing methylphenidate's efficacy in managing attention deficit hyperactivity disorder. Clinically, this interaction may result in insufficient blood pressure control or attenuated therapeutic response to methylphenidate."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WEZLANA vs METHYLPHENIDATE, answered by our medical review team.
WEZLANA is a Unknown that works by WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.. METHYLPHENIDATE is a CNS Stimulant that works by Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WEZLANA and METHYLPHENIDATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WEZLANA is: IV: 500 mg every 12 hours over 60 minutes.. The standard adult dose of METHYLPHENIDATE is: Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WEZLANA and METHYLPHENIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WEZLANA is classified as Category C. First trimester: Potential for major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects based on animal studies and limited human . METHYLPHENIDATE is classified as Category A/B. First trimester: Limited data; possible increased risk of congenital heart defects. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal sy. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.